Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
Bio2RDF identifier
NCT00297830
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00297830
identifiers.org URI
acronym [clinicaltrials_vocabulary:acronym]
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... own which one will work best.
brief title [clinicaltrials_vocabulary:brief-title]
Zoledronic Acid Versus Alendro ...... ss After Organ Transplantation
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2014-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Patients who have under ...... rays will be performed twice.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2006-02-27T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
Alendronate
Bone Density/drug effects
Comparative study
Heart Transplantation
Immunosuppression
Liver Transplantation
Zoledronic acid
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-02-11T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00297830
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Zoledronic Acid Versus Alendro ...... ss After Organ Transplantation
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2010-04-01T00:00:00Z
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
CZOL446H104
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2005-11-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-02-01T00:00:00Z
identifier
clinicaltrials:NCT00297830
title
Zoledronic Acid Versus Alendro ...... ss After Organ Transplantation
@en